Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Post by TheMadMonkon Dec 30, 2021 9:35pm
358 Views
Post# 34272818

I beg to differ

I beg to differA gamble implies that it is pure luck whether or not this company succeeds.  A shot in the dark if you will.  We have twenty years of research, sixty million in the bank, fifty plus thousand pages of published results, numerous patents, and a team of top-notch talent.  This is by no means a gamble, it is an investment, and in my opinion, it is a very good investment.  That's not to say that there is no risk in this investment, there is risk in everything that we do in life.  There is risk in crossing the street.  Everyone needs to determine if the risk reward ratio is right for them.  There are some people out there that treat this security as a form of gambling.  They buy at $6 hoping to flip it at $20 when there is a NASDAQ listing.  These are not investors, these are degenerate gamblers and if they lose money, I don't feel bad for them.  If you liked this stock at $7 you should love it at 70 cents.  Even if the acute market for OTENA is 40% smaller than for chronic, you are getting the stock for 90% less, with a shorter to market drug, and less risk.  As long as there are people willing to sell this stock at ridiculously low prices, I will be more than happy to take it off their hands. 
<< Previous
Bullboard Posts
Next >>